PE20011140A1 - Proceso para preparar forma i cristalina de cabergolina - Google Patents
Proceso para preparar forma i cristalina de cabergolinaInfo
- Publication number
- PE20011140A1 PE20011140A1 PE2001000237A PE2001000237A PE20011140A1 PE 20011140 A1 PE20011140 A1 PE 20011140A1 PE 2001000237 A PE2001000237 A PE 2001000237A PE 2001000237 A PE2001000237 A PE 2001000237A PE 20011140 A1 PE20011140 A1 PE 20011140A1
- Authority
- PE
- Peru
- Prior art keywords
- cabergolin
- cabergoline
- crystaline
- dat2
- receptors
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title abstract 3
- 229960004596 cabergoline Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 102000003946 Prolactin Human genes 0.000 abstract 2
- 108010057464 Prolactin Proteins 0.000 abstract 2
- 229940097325 prolactin Drugs 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007308.0A GB0007308D0 (en) | 2000-03-24 | 2000-03-24 | Process for preparing crystalline form | of cabergoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011140A1 true PE20011140A1 (es) | 2001-11-01 |
Family
ID=9888433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000237A PE20011140A1 (es) | 2000-03-24 | 2001-03-13 | Proceso para preparar forma i cristalina de cabergolina |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6727363B2 (https=) |
| EP (1) | EP1272489B1 (https=) |
| JP (1) | JP4184666B2 (https=) |
| KR (1) | KR100827558B1 (https=) |
| CN (1) | CN1188412C (https=) |
| AR (1) | AR032449A1 (https=) |
| AT (1) | ATE250601T1 (https=) |
| AU (2) | AU780747B2 (https=) |
| BR (1) | BR0109507A (https=) |
| CA (1) | CA2402836A1 (https=) |
| CZ (1) | CZ20023176A3 (https=) |
| DE (1) | DE60100858T2 (https=) |
| DK (1) | DK1272489T3 (https=) |
| EA (1) | EA005928B1 (https=) |
| EE (1) | EE05088B1 (https=) |
| ES (1) | ES2208602T3 (https=) |
| GB (1) | GB0007308D0 (https=) |
| HK (1) | HK1052348B (https=) |
| HU (1) | HUP0300591A3 (https=) |
| IL (2) | IL150985A0 (https=) |
| MX (1) | MXPA02009283A (https=) |
| MY (1) | MY134189A (https=) |
| NO (1) | NO20024321D0 (https=) |
| NZ (1) | NZ521316A (https=) |
| PE (1) | PE20011140A1 (https=) |
| PL (1) | PL358253A1 (https=) |
| PT (1) | PT1272489E (https=) |
| SI (1) | SI1272489T1 (https=) |
| SK (1) | SK13582002A3 (https=) |
| WO (1) | WO2001070740A1 (https=) |
| ZA (1) | ZA200206045B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| IL163779A0 (en) * | 2002-03-15 | 2005-12-18 | Pharmacia Corp | Process for preparing crystalline form i of cabergoline |
| PL374503A1 (en) * | 2002-03-15 | 2005-10-31 | Pharmacia Corporation | Process for preparing crystalline form i of cabergoline |
| IL155545A (en) | 2003-04-21 | 2009-12-24 | Finetech Pharmaceutical Ltd | Solvate form of cabergoline |
| KR20060028761A (ko) | 2003-05-08 | 2006-04-03 | 아이박스 파마슈티컬스 에스.알.오. | 다형의 카베르골린 |
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline |
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline |
| GB0515430D0 (en) * | 2005-07-27 | 2005-08-31 | Resolution Chemicals Ltd | Preparation of cabergoline |
| GB0505965D0 (en) | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline |
| EP1925616A1 (en) * | 2006-10-26 | 2008-05-28 | LEK Pharmaceuticals D.D. | Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline |
| EP1953157A1 (en) | 2007-01-31 | 2008-08-06 | LEK Pharmaceuticals D.D. | New crystal form of cabergoline |
| US8637099B2 (en) * | 2007-08-29 | 2014-01-28 | Max Zeller Sohne Ag | Use of Vitex agnus castus extracts for preparing a medicament |
| EP4074552B1 (en) * | 2021-04-16 | 2024-04-03 | Thermo King LLC | Electrical connection unit |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3019322A1 (de) | 1980-05-21 | 1981-12-03 | Merck Patent Gmbh, 6100 Darmstadt | Psychopharmakon sowie verwendung von adenosinderivaten |
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
| GB9205439D0 (en) * | 1992-03-12 | 1992-04-22 | Erba Carlo Spa | Process for the synthesis of ergoline derivatives |
| WO1995005176A1 (en) | 1993-08-18 | 1995-02-23 | Alcon Laboratories, Inc. | Use of ergoline derivatives for the treatment of glaucoma |
| JP2002509119A (ja) | 1998-01-13 | 2002-03-26 | アストラゼネカ ユーケイ リミテッド | ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物 |
| JP2002507562A (ja) | 1998-03-27 | 2002-03-12 | ファルマシア・アンド・アップジョン・カンパニー | レストレスレッグ症候群の治療におけるカベルゴリンの使用 |
| GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| GB0007307D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
-
2000
- 2000-03-24 GB GBGB0007308.0A patent/GB0007308D0/en not_active Ceased
-
2001
- 2001-03-13 PE PE2001000237A patent/PE20011140A1/es not_active Application Discontinuation
- 2001-03-19 PL PL01358253A patent/PL358253A1/xx not_active Application Discontinuation
- 2001-03-19 ES ES01936098T patent/ES2208602T3/es not_active Expired - Lifetime
- 2001-03-19 HK HK03104554.7A patent/HK1052348B/zh not_active IP Right Cessation
- 2001-03-19 WO PCT/EP2001/003099 patent/WO2001070740A1/en not_active Ceased
- 2001-03-19 EP EP01936098A patent/EP1272489B1/en not_active Expired - Lifetime
- 2001-03-19 EA EA200201016A patent/EA005928B1/ru unknown
- 2001-03-19 MX MXPA02009283A patent/MXPA02009283A/es active IP Right Grant
- 2001-03-19 CA CA002402836A patent/CA2402836A1/en not_active Withdrawn
- 2001-03-19 SK SK1358-2002A patent/SK13582002A3/sk unknown
- 2001-03-19 KR KR1020027012590A patent/KR100827558B1/ko not_active Expired - Fee Related
- 2001-03-19 DE DE60100858T patent/DE60100858T2/de not_active Expired - Fee Related
- 2001-03-19 DK DK01936098T patent/DK1272489T3/da active
- 2001-03-19 IL IL15098501A patent/IL150985A0/xx active IP Right Grant
- 2001-03-19 AR ARP010101263A patent/AR032449A1/es unknown
- 2001-03-19 CZ CZ20023176A patent/CZ20023176A3/cs unknown
- 2001-03-19 BR BR0109507-2A patent/BR0109507A/pt not_active Application Discontinuation
- 2001-03-19 AU AU62110/01A patent/AU780747B2/en not_active Ceased
- 2001-03-19 SI SI200130045T patent/SI1272489T1/xx unknown
- 2001-03-19 EE EEP200200545A patent/EE05088B1/xx not_active IP Right Cessation
- 2001-03-19 PT PT01936098T patent/PT1272489E/pt unknown
- 2001-03-19 US US10/239,636 patent/US6727363B2/en not_active Expired - Fee Related
- 2001-03-19 JP JP2001568941A patent/JP4184666B2/ja not_active Expired - Fee Related
- 2001-03-19 NZ NZ521316A patent/NZ521316A/en unknown
- 2001-03-19 CN CNB018070051A patent/CN1188412C/zh not_active Expired - Fee Related
- 2001-03-19 HU HU0300591A patent/HUP0300591A3/hu unknown
- 2001-03-19 AT AT01936098T patent/ATE250601T1/de not_active IP Right Cessation
- 2001-03-22 MY MYPI20011364A patent/MY134189A/en unknown
-
2002
- 2002-07-29 ZA ZA200206045A patent/ZA200206045B/xx unknown
- 2002-07-30 IL IL150985A patent/IL150985A/en not_active IP Right Cessation
- 2002-09-10 NO NO20024321A patent/NO20024321D0/no not_active Application Discontinuation
-
2003
- 2003-10-31 US US10/698,737 patent/US6953854B2/en not_active Expired - Fee Related
-
2005
- 2005-07-14 AU AU2005203071A patent/AU2005203071B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011140A1 (es) | Proceso para preparar forma i cristalina de cabergolina | |
| MY155394A (en) | Muscadine composition with improved anti-oxidant activity | |
| CN101581648B (zh) | 一种测定配方烟丝中薄片丝掺用比例的方法 | |
| WO2012082718A3 (en) | 3-methanesulfonylpropionitrile for treating inflammation and pain | |
| NZ596056A (en) | Lyophilization cakes of proteasome inhibitors | |
| JP2011510984A5 (https=) | ||
| NZ590682A (en) | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide | |
| CN101735888A (zh) | 一种铁皮石斛花挥发油的提取方法 | |
| TNSN07013A1 (en) | Anti-histaminic composition | |
| AR054609A1 (es) | Composiciones similares a batido que contienen agente de solidificacion y metodos para prepararlas y usarlas | |
| RU2014133099A (ru) | Применение косточки авокадо для получения масла авокадо, обогащенного алифатическими многоатомными спиртами и/или их ацетилированными производными | |
| CN102807692A (zh) | 一种再生橡胶生产用的软化剂 | |
| BR112022008930A2 (pt) | Formulação em pó seco aromatizada com tabaco melhorada | |
| EA201400802A1 (ru) | Способ приготовления курительной композиции без табака для кальяна | |
| PE20011087A1 (es) | Forma ii cristalina de cabergolina | |
| TW200604209A (en) | Moisture retention polymer compound | |
| GB0118300D0 (en) | Formulations | |
| PE108798A1 (es) | Compuestos de naftilo, intermedios, composiciones y procedimientos de uso | |
| Mikail et al. | New alkylresorcinols from a lipophilic extract of Urginea indica L. bulbs showing experimental trauma healing activity | |
| Saqib et al. | DFT for exploring the antioxidant potential of homogentisic and orsellinic acids | |
| PE20001487A1 (es) | 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos con n-(5-fenil-tetrahidrofuranil) metilo y n-(6-fenil-tetrahidropiranil) metilo; procedimientos para prepararlos y su empleo como composiciones farmaceuticas | |
| CN101773283A (zh) | 一种组合膨胀烟丝 | |
| PE20221446A1 (es) | Nuevas formulaciones de comprimido de fosfomicina | |
| Threrapanithan et al. | Anti-inflammatory and antioxidant activities of the Thai traditional remedy called “Leard-ngam” and its plant ingredients | |
| CA2455566C (en) | (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |